Ruxolitinib for Steroid-Refractory GVHD: The REACH Trials

Yi-Bin Chen, MD, delineates between acute and chronic GVHD and provides the incidence and risk factors associated with these diseases.

Dr Yi-Bin Chen describes several prophylactic regimens commonly used to prevent GVHD following allogeneic hematopoietic stem cell transplant.

An expert in bone marrow transplantation outlines the main therapy used in the front-line setting to treat GVHD and then provides several definitions of what it means to be steroid-refractory.

Yi-Bin Chen, MD, discusses several approaches to the treatment of steroid-refractory acute GVHD, along with the immunologic pathways they target.

Dr Yi-Bin Chen reviews treatment options for patients with steroid-refractory chronic GVHD.

Key opinion leader, Yi-Bin Chen, MD, summarizes the clinical trial data supporting the recent FDA approval of ruxolitinib for the treatment of steroid-refractory acute GVHD and provides insights on a potential future role for ruxolitinib in steroid-refractory chronic GVHD.

Dr Yi-Bin Chen shares his thoughts on future directions and unmet needs in treatment of steroid-refractory GVHD.